Genelabs Technologies Announces Presentation of Data on Non-Nucleoside HCV Polymerase Inhibitor at the 15th International Sym...
09 Octubre 2008 - 11:15AM
Business Wire
Genelabs Technologies, Inc. (Nasdaq:GNLB) announced that three
presentations were made at the 15th International Symposium on
Hepatitis C Virus and Related Viruses, each on a non-nucleoside
hepatitis C virus (HCV) polymerase inhibitor discovered by
Genelabs. The presentations focused on the discovery, in vitro
antiviral activity, resistance profile, pharmacokinetics and
mechanism of action of GL60667 (NVP-LDI133), a potent
non-nucleoside inhibitor of the HCV NS5B polymerase. The
presentations contain studies performed by both Genelabs and
Novartis scientists in connection with the license and research
collaboration commenced in June of 2006 between the companies,
covering Genelabs non-nucleoside HCV polymerase inhibitors. GL60667
is one of a number of non-nucleoside HCV polymerase inhibitors
discovered by Genelabs. �The presentations made describe the
discovery of new site 1 non-nucleoside polymerase inhibitors with
potent anti-HCV activity� said Ronald C. Griffith, Ph.D., Genelabs�
Chief Scientific Officer. �Other compounds from this class continue
to advance forward in preclinical studies and we are very pleased
with the progress made to date.� About Genelabs Technologies
Genelabs is a biopharmaceutical company focused on the discovery
and development of novel compounds for infectious diseases. In
addition to a late-stage vaccine candidate for hepatitis E virus
partnered with GlaxoSmithKline, the company is advancing both
partnered and proprietary compounds designed to selectively inhibit
replication of the hepatitis C virus. For more information, please
visit www.genelabs.com. NOTE ON FORWARD LOOKING STATEMENTS AND
RISKS: This press release contains forward-looking statements
regarding the quality and continued development of a therapeutic
compound for the treatment of HCV infection. These forward-looking
statements are based on Genelabs� current expectations and are
subject to uncertainties and risks that could cause actual results
to differ materially from the statements made, including, without
limitation, uncertainties and risks associated with the preclinical
development of therapeutic compounds and the continued commitment
of Genelabs� collaborative partner. Please see the information
appearing in the company's filings with the Securities and Exchange
+Commission, including the most recent Annual Report on Form 10-K
and Quarterly Reports on Form 10-Q, under the captions �Risk
Factors,� �Business Risks� and �Forward-Looking Statements� for
more discussion regarding these uncertainties and risks and other
risks that may cause actual results to differ from those included
in the forward-looking statements. Genelabs does not undertake any
obligation to update these forward-looking statements or risks to
reflect events or circumstances after the date of this release.
Genelabs (NASDAQ:GNLB)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Genelabs (NASDAQ:GNLB)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Genelabs Technologies (MM) (NASDAQ): 0 recent articles
Más de Genelabs Technologies, Inc. Artículos de Noticias